ALK and non-small cell lung carcinoma: Better tolerated, more targeted, and individually tailored systemic therapies for NSCLC, including epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib, and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; immune checkpoint inhibitors, pembrolizumab, nivolumab, and atezolizumab; and the anti-vascular endothelial growth factor receptor monoclonal antibody bevacizumab, have also revolutionized the treatment, reducing mortality [36,37].